The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The phase Ib result of the safety and efficacy of lenvatinib (lenv) plus eribulin (eri) in advanced adipocytic sarcoma (LPS) and leiomyosarcoma (LMS): LEADER study (NCT03526679).
 
Tom Wei-Wu Chen
Honoraria - Eisai; Lilly; Novartis
Consulting or Advisory Role - Eisai
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai
 
Ruey-Long Hong
Research Funding - Lilly
 
Chueh-Chuan Yen
Honoraria - Amgen; Eisai; Lilly; MSD
Consulting or Advisory Role - Lilly; MSD
Research Funding - Efficient Pharma Management Corp.; Eisai; Lilly; Ono Pharmaceutical; Taiwan Liposome Company
Travel, Accommodations, Expenses - MSD; Ono Pharmaceutical; Roche
 
San-Chi Chen
No Relationships to Disclose
 
Jhe-Cyuan Guo
Honoraria - Astellas Pharma; MSD; Ono Pharmaceutical
 
Meng-Chi Hsu
No Relationships to Disclose
 
Ting-Fang Kung
No Relationships to Disclose